Dapagliflozin in acute heart failure management: a systematic review and meta-analysis of safety and effectiveness.

ABSTRACT:

Background

Acute Heart Failure (AHF) presents as a serious pathophysiological disease with significant morbidity and mortality rates, requiring immediate medical intervention. Traditional treatment involves diuretics and vasodilators, but a subset of patients develop resistance due to acute cardiorenal syndrome. Dapagliflozin, categorized as a sodium-glucose cotransporter-2 inhibitor (SGLT2i), has emerged as a promising therapy for AHF, demonstrating substantial benefits in reducing both mortality and morbidity among patients. The purpose of this meta-analysis and systematic review is to determine dapagliflozin's safety and efficacy in AHF patients.

Methods

In accordance with PRISMA guidelines, we conducted a systematic search across several databases (PubMed, Science Direct

SUBMITTER: Raja A 

PROVIDER: S-EPMC11681638 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature